Zacks Initiates Coverage of Aspira With Neutral Recommendation
Discover why Zacks rates Aspira as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore AWHL's AI-powered endometriosis diagnostic opportunity and expanding women's health platform amid liquidity concerns and commercialization risks.